Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call

2 years ago

ROSELAND, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments,…

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

2 years ago

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

2 years ago

COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc…

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

2 years ago

Company to disclose new programs from existing unnamed pre-clinical pipelineCAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.…

TransCode Therapeutics Open Letter to Shareholders

2 years ago

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following…

Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

2 years ago

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism…

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

2 years ago

– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by…

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

2 years ago

-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a…

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

2 years ago

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in…

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

2 years ago

Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4…